ReviewFrontiers in immunology2026
Diet, hormones, and breast cancer: biomarker-guided assessment of risk and prognosis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite growing recognition that nutritional factors modulate breast cancer risk and prognosis through endocrine and metabolic pathways, existing reviews have predominantly focused on individual nutrients or single hormonal axes, lacking an integrated framework that systematically connects nutritional biomarkers across biological scales to clinical prediction models. Furthermore, the translational gap between biomarker discovery and clinical implementation-compounded by pre-analytical variability, population heterogeneity, and the absence of standardized testing protocols-remains inadequately addressed in the current literature. This review synthesizes contemporary evidence on nutritional biomarkers and their interactions with endocrine-related mechanisms in breast cancer, with a specific focus on risk assessment and prognosis prediction. We systematically integrate four core endocrine-metabolic axes (estrogen signaling, insulin/IGF-1 pathway, adipokine homeostasis, and inflammatory-oxidative stress) with four functional classes of nutritional biomarkers (recovery, concentration, replacement, and predictive), delineating their hierarchical relationships and complementary clinical roles. We further examine subtype-specific metabolomic signatures associated with differential prognosis across triple-negative, luminal-like, and HER2-enriched breast cancer, and evaluate the clinical utility of integrating multi-dimensional biomarkers into prognostic prediction models including nomograms. Our analysis reveals that while circulating vitamins, fatty acid profiles, and inflammatory biomarkers demonstrate consistent associations with breast cancer risk, their prognostic value varies substantially by molecular subtype and menopausal status; composite metabolomic signatures outperform single biomarkers in prognostic discrimination, yet most evidence derives from retrospective single-center cohorts with limited external validation. We conclude that biomarker-guided precision nutrition holds substantial promise for advancing personalized breast cancer prevention and management, but critical barriers-including non-standardized assay protocols, underrepresentation of non-Western populations, and a paucity of prospective intervention trials-must be addressed before widespread clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.